A method for simultaneous detection of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester in cosmetics.

By employing high-performance liquid chromatography (HPLC) and personalized pretreatment methods, the detection challenges of various anti-hair loss drugs in cosmetics have been solved. This has enabled the accurate detection of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester, thereby improving the precision and reliability of cosmetic testing.

CN120102740BActive Publication Date: 2026-11-10SHANGHAI INST FOR FOOD & DRUG CONTROL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510266638.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-03-06
Publication Date
2026-11-10
Estimated Expiration
2045-03-06

AI Technical Summary

Technical Problem

Existing technologies are insufficient to simultaneously and accurately detect the contents of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester in cosmetics, especially in complex cosmetic matrices where detection methods are inadequate.

Method used

High-performance liquid chromatography (HPLC) was employed, using phosphoric acid aqueous solution and methanol as the mobile phase for gradient elution. Combined with personalized pretreatment methods, the method was used to detect different cosmetic matrix types, including a layered extraction step using 90% methanol and n-hexane. The chromatographic conditions were optimized to achieve stable separation and detection of a variety of compounds.

Benefits of technology

It enables highly precise quantitative analysis of different cosmetic matrices, reduces sample pretreatment steps, improves the accuracy and reliability of detection results, and fills the gap in the detection of hair growth-promoting ingredients in cosmetics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120102740B_ABST
    Figure CN120102740B_ABST
Patent Text Reader

Abstract

This application discloses a method for the simultaneous detection of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester in cosmetics. The method provided in this application can rapidly, completely, and accurately extract these four compounds, including diaminopyrimidine oxide, from cosmetics. This invention employs high-performance liquid chromatography (HPLC), a simple, efficient, and easy-to-implement method for the simultaneous determination of these four compounds in cosmetics. Using this method, samples can be extracted with an extraction solvent without derivatization and directly analyzed by HPLC. The method is simple, easy to operate, highly versatile, reproducible, has a high recovery rate, and provides accurate results. It will help improve the quality and safety supervision of cosmetics, providing important technical support for the industry's regulatory needs and meeting the requirements of cosmetic quality and safety supervision.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of analytical testing, and in particular to a method for the simultaneous detection of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin and chloroprostol isopropyl ester in cosmetics. Background Technology

[0002] Diaminopyrimidine oxide (2,4-diaminopyrimidine 3-oxide) and pyrrolyl diaminopyrimidine oxide (Kopyrrol) are functional ingredients in cosmetics used to prevent hair loss and promote hair growth. Diaminopyrimidine oxide can effectively inhibit hair thinning or induce and stimulate hair growth in cosmetics, and can be used to treat baldness, alopecia areata, etc. Pyrrolyl diaminopyrimidine oxide (Kopyrrol) is a novel hair growth promoter that can effectively promote the proliferation of dermal papilla cells. Compared with minoxidil, it has effects such as preventing hair loss and restoring hair follicle activity. Currently, both pyrrolyl diaminopyrimidine and diaminopyrimidine oxide are included in the "List of Used Cosmetic Ingredients" (2021 edition), allowing them to be added to cosmetics.

[0003] Metformin is a medication used to treat stage 2 diabetes. Further research has revealed that topical metformin can induce autophagy and hair regrowth. Isopropylcloprostenate is a 5α-reductase inhibitor. By inhibiting 5α-reductase activity, it promotes hair growth, particularly eyelashes. However, long-term use of cloprostenate can irritate the eyes, causing iris darkening, iritis, and even blindness. Both metformin and cloprostenate are currently prohibited in cosmetics. However, due to their hair-promoting effects, some unscrupulous cosmetic manufacturers illegally add these two compounds to their products in an attempt to promote hair or eyelash growth.

[0004] Currently, most methods for detecting metformin are focused on pharmaceuticals and biological products, employing analytical techniques primarily such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), and thin-layer chromatography (TLC). There are very few literature reports on methods for determining metformin content in cosmetics. Similarly, there are few literature reports on methods for determining chloroprostol isopropyl ester in cosmetics. Some literature reports the use of HPLC to determine diaminopyrimidine oxides in cosmetics, but no literature reports have been found on methods for determining the content of pyrrolidine diaminopyrimidine oxides in cosmetics.

[0005] In summary, there are currently few reported methods for detecting anti-hair loss drugs in cosmetics. No domestic or international literature reports the simultaneous determination of four anti-hair loss drugs—diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester—in cosmetics using high-performance liquid chromatography (HPLC). Furthermore, due to the complexity of cosmetic matrices, it is difficult to accurately measure these anti-hair loss substances using methods from the field of chemical pharmaceuticals. Summary of the Invention

[0006] The purpose of this application is to provide a method for simultaneously detecting diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester in cosmetics.

[0007] To address the aforementioned technical problems, a first aspect of this application provides a method for simultaneously detecting diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester in cosmetics, the method comprising the steps of:

[0008] Liquid chromatography (LC) was used to detect whether the cosmetic product contained diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin (or metformin hydrochloride), and chloroprostol isopropyl ester. The chromatographic conditions for LC included gradient elution using an aqueous solution of phosphoric acid as the aqueous phase and methanol as the organic phase. The gradient elution procedure was as follows:

[0009] Time (min) Aqueous phase (v / v%) Organic phase (v / v%) 0 90 10 20 10 90 30 10 90 30.01 90 10 35 90 10 .

[0010] In one embodiment, the aqueous solution of phosphoric acid has a phosphoric acid mass concentration of 85%.

[0011] In one embodiment, the chromatographic conditions further include:

[0012] Chromatographic column: C18 column (preferably AQ-C18 column);

[0013] Column temperature: 25-35℃ (e.g., 30℃);

[0014] Flow rate: 0.6-1.2 mL / min (0.8 mL / min); and / or

[0015] Injection volume: 5-15 μL (e.g., 10 μL).

[0016] In one embodiment, the liquid chromatography is high-performance liquid chromatography (HPLC), and the detection wavelength set on the HPLC includes:

[0017] Diaminopyrimidine oxide: 287nm;

[0018] Pyrrolidinyl diaminopyrimidine oxide: 228 nm;

[0019] Metformin: 233nm; and

[0020] Chloroprostanol isopropyl ester: 228nm.

[0021] In one embodiment, the sample to be tested includes a pretreatment step: ultrasonic treatment with 90% methanol, followed by mixing with n-hexane, allowing the mixture to stand and separate into layers, and then taking the clear layer as the sample solution to be tested; preferably, the sample solution to be tested is filtered through a filter membrane.

[0022] In one embodiment, the sample to be tested is selected from at least one of aqueous solutions, oils, creams, emulsions, gels, and powders. The sample to be tested includes a pretreatment step: ultrasonic treatment of the sample to be tested with 90% methanol, followed by mixing with n-hexane, allowing it to stand and separate into layers, and then taking the clear lower layer as the sample solution to be tested. Preferably, the sample solution to be tested is filtered through a filter membrane.

[0023] In one embodiment, the sample to be tested is selected from at least one of aqueous solutions, oils, creams, emulsions, gels, and powders. The sample to be tested includes a pretreatment step: weigh 1g of the sample to be tested into a stoppered colorimetric tube, accurately add 20ml of 90% methanol solution, vortex mix, sonicate (preferably sonicate for a time not less than 10-20min (e.g., 15min)), add 10ml of n-hexane, vortex (preferably vortex for a time not less than 1min), centrifuge at 10000rpm for 5min, allow to stand and separate into layers, take the lower clear layer and filter it through a 0.45μm filter membrane to obtain the sample solution to be tested.

[0024] In one embodiment, the sample to be tested is a wax-based sample, and the sample to be tested includes a pretreatment step: treating the sample to be tested with tetrahydrofuran, then adding 90% methanol solution and ultrasonically treating the sample to be tested, then adding n-hexane and mixing, allowing it to stand and separate into layers, and taking the lower clear liquid as the sample solution to be tested; preferably, the sample solution to be tested is filtered through a filter membrane.

[0025] In one embodiment, the sample to be tested is a wax-based sample, and the sample to be tested includes a pretreatment step: weigh 1g of the sample to be tested into a stoppered colorimetric tube, accurately add 1ml of tetrahydrofuran solution, vortex to dissolve the sample, then accurately add 19ml of 90% methanol solution, vortex to mix, sonicate (preferably for a time not less than 10-20min (e.g., 15min)), add 10ml of n-hexane, vortex (preferably for a time not less than 1min), centrifuge at 10000rpm for 5min, allow to stand for separation, take the lower clear liquid and filter it through a 0.45μm filter membrane to obtain the sample solution to be tested.

[0026] In one implementation, the method includes the steps of:

[0027] Step 1: Prepare standard solutions of diaminopyrimidine oxide, pyrrolidinyl diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester at different concentrations using methanol as the solvent;

[0028] Step 2: High performance liquid chromatography (HPLC) was used to detect the different concentrations of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester standard solutions obtained in Step 1. Based on the concentrations of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester and the instrument response values, standard curves for diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester were plotted.

[0029] Step 3: Detect the sample solution under the same test conditions as in Step 2, and calculate the contents of diaminopyrimidine oxide, pyrrolidinyl diaminopyrimidine oxide, metformin and chloroprostol isopropyl ester according to the standard curve obtained in Step 2.

[0030] The chromatographic conditions in step two include: using an aqueous solution of phosphoric acid as the aqueous phase and methanol as the organic phase for gradient elution, the gradient elution procedure of which is as follows:

[0031] Time (min) Aqueous phase (v / v%) Organic phase (v / v%) 0 90 10 20 10 90 30 10 90 30.01 90 10 35 90 10 .

[0032] In one embodiment, the concentrations of the different concentrations of the diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester standard solutions are selected from at least three of 0.1 μg / mL, 0.5 μg / mL, 1 μg / mL, 5 μg / mL, 10 μg / mL, 50 μg / mL, 100 μg / mL, and 200 μg / mL, more preferably at least four, and more preferably at least five.

[0033] In one embodiment, the cosmetic is an aqueous solution, an oil-based product, a cream, an emulsion, a wax-based product, a gel, or a powder.

[0034] In one embodiment, the cosmetic is a hair cleaning or care product, such as a hair cleaning or care product, a beard cleaning or care product, or an eyelash or eyebrow cleaning or care product.

[0035] In one embodiment, the cosmetic is shampoo, shower gel, conditioner, hair dye, perm cream, hair mask, hair oil, hair wax, styling spray, hair gel, hair lotion, hair sunscreen spray, hair growth serum, beard cream, beard oil, beard growth serum, beard lotion, eyebrow dye, hair dye, eyebrow pencil, eyebrow powder, eyebrow growth serum, eyelash growth serum, and eyelash setting serum.

[0036] Based on the prior art, the present invention has at least the following advantages:

[0037] 1. The method of this invention employs targeted and personalized pretreatment methods for different cosmetic matrix types. It can complete the detection of multiple compounds in a short time, reduce sample pretreatment steps, provide high-precision quantitative analysis, has good data repeatability, high recovery rate, accurate detection results, and high reliability, filling the gap in the determination of hair growth-promoting functional ingredients and prohibited components in cosmetics.

[0038] 2. In the embodiments of the present invention, various extraction solutions were screened. A 10% methanol solution was used to extract four compounds, including diaminopyrimidine oxide, from the sample. It was found that the recovery rate of chloroprostol isopropyl ester in the sample was essentially 0%. Subsequently, 30% methanol, 50% methanol, 70% methanol, and 90% methanol solutions were used sequentially as extraction solutions. It was found that the 90% methanol solution had the highest recovery rate, and therefore, the 90% methanol solution was ultimately selected as the extraction solution.

[0039] 3. In the embodiments of the present invention, the conditions of the mobile phase were screened: using methanol as the organic phase, the separation effects of three different aqueous phase systems—0.1% phosphoric acid, 1.7% dihydrogen phosphate (pH=3), and water—on the four compounds were investigated. The results showed that when water was used as the aqueous phase, diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, and metformin all exhibited stable peak elution, but chloroprostol isopropyl ester showed strong retention on the column and could not be eluted. When using 1.7% dihydrogen phosphate (pH=3) as the aqueous phase, chloroprostol isopropyl ester was found to elute when the organic phase ratio was relatively high, but the peak area response value was small and did not meet the sensitivity requirements for determination. When 0.1% phosphoric acid was used as the aqueous phase, all four compounds eluted, and the separation effect was satisfactory. Therefore, 0.1% phosphoric acid and methanol were used as the mobile phase system.

[0040] 4. In the embodiments of the present invention, different pretreatment methods were developed for different matrices: For wax-based products, our experiments found that the recovery rate of some wax-based products using Method 1 could reach more than 80%, but the recovery rate of most wax-based products was relatively low, only between 50-60%. Later, a dissolution step with tetrahydrofuran was added in the pretreatment process, and it was found that the recovery rate was generally improved to 80-90%. Therefore, the present invention selected different pretreatment methods for wax-based products.

[0041] It should be understood that, within the scope of this application, the above-described technical features of this application and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0042] One or more embodiments are illustrated by way of example with reference to the accompanying drawings, and these illustrative descriptions do not constitute a limitation on the embodiments.

[0043] Figure 1 This is a high-performance liquid chromatogram of the standard solution of diaminopyrimidine oxide (1) according to an embodiment of the present invention, with a detection wavelength of 287 nm;

[0044] Figure 2 The high-performance liquid chromatogram of the standard solutions of pyrrolidinyl diaminopyrimidine oxide (2) and chloroprostol isopropyl ester (4) in the embodiments of the present invention is shown. The detection wavelength is 228 nm.

[0045] Figure 3 The high-performance liquid chromatogram of metformin (3) standard solution according to the present invention, with a detection wavelength of 233 nm;

[0046] Figure 4 This is a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS) spectrum of the standard solution of diaminopyrimidine oxide (1) according to an embodiment of the present invention;

[0047] Figure 5 This is a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS) spectrum of the standard solution of pyrrolidinyl diaminopyrimidine oxide (2) according to an embodiment of the present invention;

[0048] Figure 6 This is a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS) spectrum of metformin (3) standard solution according to an embodiment of the present invention;

[0049] Figure 7 This is a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS) spectrum of the chloroprostol isopropyl ester (4) standard solution according to an embodiment of the present invention. Detailed Implementation

[0050] Through extensive and in-depth research, the inventors have developed a method for the simultaneous detection of four compounds in cosmetics: diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester. This method avoids derivatization by optimizing the pretreatment process and improves the recovery rate, linear range, accuracy, and repeatability by optimizing the chromatographic conditions. It overcomes the deficiency of one-step detection of prohibited substances such as diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester in hair products, and provides important technical support for the industry supervision of cosmetics, meeting the needs of cosmetic quality and safety supervision.

[0051] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the present application is further described below in conjunction with specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of this application. Experimental methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts. Unless otherwise specified, the experimental materials and reagents used in the following embodiments are commercially available.

[0052] Unless otherwise specified, the technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains. It should be noted that the terms used herein are for the purpose of describing particular embodiments only and are not intended to limit the exemplary embodiments of this application.

[0053] Example 1

[0054] This embodiment provides a method for detecting four compounds, including diaminopyrimidine oxide, in cosmetics. The method parameters are as follows:

[0055] 1. Reagents and Materials

[0056] Unless otherwise specified, all reagents used in this method are of analytical grade or higher, and the water is Grade I water as specified in GB / T 6682.

[0057] 1.1. Standard products, see Table 1-1.

[0058] Table 1-1 Standard Product Information Table

[0059]

[0060] Note: When the standard product differs from the target component, necessary conversions are required.

[0061] 1.2. Methanol, chromatographic grade.

[0062] 1.3. Tetrahydrofuran, analytical grade.

[0063] 1.4. n-Hexane

[0064] 1.5. Phosphoric acid (85%), superior grade.

[0065] 1.6. Formic acid, chromatographic grade.

[0066] 1.7.90% Methanol: Accurately measure 900.0 mL of methanol (1.2), add ultrapure water to 1000 mL, mix well, and the product is ready.

[0067] 1.8.0.1% Phosphoric acid solution: Accurately measure 1.0 mL of phosphoric acid (1.5), add ultrapure water to 1000 mL, mix well, and filter through a 0.45 μm filter membrane to obtain the solution.

[0068] 1.9.0.01% Formic Acid Solution: Accurately measure 0.1 mL of formic acid (1.6), add ultrapure water to 1000 mL, mix well, and filter through a 0.45 μm filter membrane to obtain the solution.

[0069] 1.10. Standard Stock Solution (ρ = 1 g / L): Accurately weigh 0.01 g (accurate to 0.0001 g) of each of the following standard substances (1.1): diaminopyrimidine oxide, pyrrolyl diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester, respectively, into a 10 mL volumetric flask. Dissolve in methanol (1.2) and dilute to the mark. Shake well to obtain the standard stock solution of diaminopyrimidine oxide, pyrrolyl diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester. Store at -18°C protected from light.

[0070] 1.11. Standard series solutions

[0071] Accurately pipette an appropriate amount of the 1.10 standard stock mixed solution and dilute it with 90% methanol (1.7) to prepare a series of standard solutions with mass concentrations of 0.1, 0.5, 1, 5, 10, 50, 100 and 200 μg / mL for diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin and chloroprostol isopropyl ester.

[0072] 2. Instruments and equipment

[0073] 2.1. High performance liquid chromatograph, ultraviolet detector.

[0074] 2.2. Analytical balance: sensitivity 0.0001g and 0.00001g.

[0075] 2.3. High-speed centrifuge (speed ≥ 10000 rpm).

[0076] 2.4. Vortex mixer.

[0077] 2.5. Ultrasonic Cleaner

[0078] 3. Sample processing

[0079] For aqueous solutions, oil-based solutions, creams, emulsions, gels, or powders: Weigh 1g of the sample (accurate to 0.001g) into a 50mL stoppered colorimetric tube, accurately add 20ml of 90% methanol (1.7), vortex to mix, sonicate for 15min, add 10ml of n-hexane (1.4), vortex for 1min, centrifuge at 10000rpm for 5min, and filter the lower supernatant through a 0.45μm filter membrane as the test solution.

[0080] Wax-based: Weigh 1g of the sample to be tested and place it in a stoppered colorimetric tube. Accurately add 1ml of tetrahydrofuran (1.3), vortex to dissolve the sample, then accurately add 19ml of 90% methanol (1.7), vortex to mix, and sonicate (preferably for a time not less than 10-20 min, e.g., 15 min). Then add 10ml of n-hexane (1.4), vortex (preferably for a time not less than 1 min), centrifuge at 10000 rpm for 5 min, and allow to stand to separate into layers. Take the lower clear layer and filter it through a 0.45μm filter membrane to obtain the sample solution to be tested.

[0081] 4. Testing

[0082] Sample solutions and standard series solutions containing four compounds, including diaminopyrimidine oxide, were connected to a high-performance liquid chromatography (HPLC) system for detection.

[0083] High performance liquid chromatography conditions:

[0084] Chromatographic column: AQ-C18 column (250mm×4.6mm×5μm), or equivalent column;

[0085] Column temperature: 30℃;

[0086] Mobile phase: Solution A: 0.1% phosphoric acid solution (1.6); Solution B: methanol (1.2), gradient elution program is shown in Table 1-2.

[0087] Table 1-2 Gradient elution program

[0088] Time (min) A(%) B(%) 0 90 10 20 10 90 30 10 90 30.01 90 10 35 90 10

[0089] Flow rate: 0.8 mL / min;

[0090] Injection volume: 10 μL;

[0091] Detection wavelengths: Diaminopyrimidine oxide: 287 nm; Pyrrolidinyl diaminopyrimidine oxide: 228 nm; Metformin: 233 nm; Chloroprene isopropyl ester: 228 nm.

[0092] The oxidation of diaminopyrimidine, pyrrolidine diaminopyrimidine, metformin, and chloroprostol isopropyl ester standards were detected using the same liquid chromatography conditions on a liquid chromatography-mass spectrometry (LC-MS) system. See the attached figure for their chromatograms. Figure 4-7 .

[0093] Example 2

[0094] In this embodiment, the sample spike recovery rate of the method was investigated. The positive sample spike determination method involved selecting six positive samples containing diaminopyrimidine oxide or pyrrolidinyl diaminopyrimidine oxide, performing a positive spike test, adding an amount of the analyte equivalent to the sample amount, and determining the recovery rate. Sample information is detailed in Table 2-1.

[0095] Table 2-1 Sample Information

[0096] Sample Name Ingredient label matrix type Cosmetics A Diaminopyrimidine oxide Liquid water-based agents Cosmetics B Diaminopyrimidine oxide Oils Cosmetics C Diaminopyrimidine oxide Creams and lotions Cosmetics D pyrrolidinyl diaminopyrimidine oxide Liquid water-based agents Cosmetics E pyrrolidinyl diaminopyrimidine oxide Oils Cosmetics F pyrrolidinyl diaminopyrimidine oxide Creams and lotions

[0097] 1. Instruments and reagents

[0098] Agilent 1260 high-performance liquid chromatograph (Agilent Technologies, USA); Sartorius CP224S and 225D-1CN electronic balances (Sartorius, Germany); 5800 ultrasonic analyzer (Branson, USA); MS3 vortex mixer (IKA, Germany); 5810R benchtop centrifuge (Eppendof, Germany); Milli-Q Reference A+ ultrapure water system (Millipore, USA).

[0099] Diaminopyrimidine oxide standard (95% purity, Bieder Pharmaceutical Co., Ltd.); pyrrolidine diaminopyrimidine oxide (97% purity, Bieder Pharmaceutical Co., Ltd.); metformin (100% purity, China National Institutes for Food and Drug Control); chloroprostol isopropyl ester standard (98% purity, Shanghai Maclean Biotechnology Co., Ltd.); methanol (chromatographic grade, Merk GmbH, Germany); phosphoric acid (analytical grade, Shanghai Lingfeng Chemical Reagent Co., Ltd.); tetrahydrofuran (analytical grade, Fisher Scientific, USA); n-hexane (analytical grade, Shanghai Lingfeng Chemical Reagent Co., Ltd.); formic acid (chromatographic grade, Shanghai Anpu Experimental Technology Co., Ltd.); Shanghai Titan Technology Co., Ltd. All water used was ultrapure water.

[0100] 2.2. Chromatographic conditions

[0101] Chromatographic column: AQ-C18 column (250mm×4.6mm×5μm), or equivalent column;

[0102] Column temperature: 30℃;

[0103] Mobile phase: Solution A: 0.1% phosphoric acid solution (1.8); Solution B: methanol (1.2), gradient elution program is shown in Table 2-2.

[0104] Table 2-2

[0105] Time (min) A(%) B(%) 0 90 10 20 10 90 30 10 90 30.01 90 10 35 90 10

[0106] Flow rate: 0.8 mL / min;

[0107] Injection volume: 10 μL;

[0108] Detection wavelengths: Diaminopyrimidine oxide: 287 nm; Pyrrolidinyl diaminopyrimidine oxide: 228 nm; Metformin: 233 nm; Chloroprene isopropyl ester: 228 nm.

[0109] 3. Determination of linearity in the HPLC system:

[0110] Standard stock solutions (1 mg / mL) of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester: Accurately weigh 10 mg each of the standards for diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester into a 10 mL volumetric flask. Dissolve each standard in methanol and dilute to the mark. Shake well to prepare standard stock solutions with a concentration of 1 mg / mL for each of the three substances. Store at -20°C protected from light.

[0111] Standard series solutions: Accurately pipette an appropriate amount of standard stock solution and dilute it with 90% methanol to prepare a series of standard solutions with mass concentrations of 0.1, 0.5, 1, 5, 10, 50, 100 and 200 μg / mL for diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin and chloroprostol isopropyl ester.

[0112] Linear regression analysis was performed with peak area as the ordinate (y) and concentration as the abscissa (x, μg / mL), and the linear equations are shown in Table 2-3 below.

[0113] Table 2-3

[0114]

[0115] 4. Sample Solution Preparation for Positive Sample Spike Recovery: Take 1.0 g (accurate to 0.001 g) each of the positive samples of diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide (DPD) (accurate to 0.001 g), and accurately add an equivalent amount of DPD or pyrrolidinyl DPD standard to each sample. Place the samples in a 50 mL stoppered colorimetric tube, accurately add 20 mL of 90% methanol solution, vortex to mix, sonicate for 15 min, add 10 mL of n-hexane solution, vortex for 1 min, centrifuge at 10000 rpm for 5 min, and filter the supernatant through a 0.45 μm filter membrane as the test solution. Prepare the test solution according to the method, which is used as the recovery solution. Repeat the experiment 6 times for each spike level, and calculate the recovery rate and relative standard deviation (n=6).

[0116] The diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide in the sample were calculated according to formula (1):

[0117] (1)

[0118] In the formula: ω—content of diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide in cosmetics, %;

[0119] m—sample volume, g;

[0120] ρ — Mass concentration of diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide in the cosmetic sample, calculated by substituting into the standard curve, in μg / mL;

[0121] V – Fixed volume, mL.

[0122] Under chromatographic conditions, the standard working curve solution and the sample solution were injected separately, and qualitative analysis was performed based on retention time and the spectrum of the diode array. The content of diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide in the sample solution was determined from the standard curve. The response values ​​of diaminopyrimidine oxide and pyrrolidinyl diaminopyrimidine oxide in the sample solution should be within the linear range of the standard curve. If they exceed the linear range, the extract should be diluted and measured again, or the amount of extract should be increased and the test repeated. The results of the positive spiked recovery rate determination are shown in Tables 2-4 and 2-5, indicating that the recovery rate determination yielded satisfactory results.

[0123] Table 2-4 Results of positive spike recovery tests for diaminopyrimidine oxides with different matrices

[0124]

[0125] Table 2-5 Results of positive spike recovery tests for pyrrolidinyl diaminopyrimidine oxides with different matrices

[0126]

[0127]

[0128] Example 3

[0129] Blank sample spiked determination: Six blank matrix samples, namely liquid water, cream emulsion, wax-based, oil, gel and powder, which do not contain four compounds including diaminopyrimidine oxide, were taken and subjected to blank spiked test to determine the recovery rate.

[0130] 1. Instruments and reagents

[0131] Same as Example 1 above.

[0132] 2. Chromatographic conditions

[0133] Same as Example 1 above.

[0134] 3. Determination of linearity in the HPLC system

[0135] Same as Example 1 above.

[0136] 4. Sample preparation for blank sample spike recovery:

[0137] For aqueous solutions, oil-based solutions, creams, emulsions, gels, or powders: Weigh 1 g of sample (accurate to 0.001 g) into a 50 mL stoppered colorimetric tube, accurately add 20 mL of 90% methanol, vortex to mix, sonicate for 15 min, add 10 mL of n-hexane, vortex for 1 min, centrifuge at 10000 rpm for 5 min, and filter the supernatant through a 0.45 μm filter membrane as the test solution. Prepare the test solution according to the method, as the recovery solution. Repeat the experiment 6 times for each spiking level, and calculate the recovery rate and relative standard deviation (n=6).

[0138] For wax-based samples: Weigh 1g of the sample to be tested into a stoppered colorimetric tube, accurately add 1ml of tetrahydrofuran, vortex to dissolve the sample, then accurately add 19ml of 90% methanol, vortex to mix, sonicate for 15min, add 10ml of n-hexane, vortex for 1min, centrifuge at 10000rpm for 5min, and filter the supernatant through a 0.45μm filter membrane as the test solution. Prepare the test solution according to the method, as the recovery solution. Repeat the experiment 6 times for each spiking level, and calculate the recovery rate and relative standard deviation (n=6).

[0139] The four compounds, including diaminopyrimidine oxide, in the sample were calculated according to formula (1):

[0140] (1)

[0141] In the formula: ω—content of four compounds, including diaminopyrimidine oxide, in cosmetics, in %;

[0142] m—sample volume, g;

[0143] ρ — the mass concentration of four compounds, including diaminopyrimidine oxide, in the cosmetic sample, calculated by substituting into the standard curve, in μg / mL;

[0144] V – Fixed volume, mL.

[0145] Under chromatographic conditions, the standard working curve solution and the sample solution were injected separately, and qualitative analysis was performed based on the retention time and the spectrum of the diode array. The content of four compounds, including diaminopyrimidine oxide, in the sample solution was determined from the standard curve. The response values ​​of the four compounds, including diaminopyrimidine oxide, in the sample solution should be within the linear range of the standard curve. If they exceed the linear range, the extract should be diluted and measured again, or the amount of extract should be increased and the test repeated.

[0146] The results of the positive spike recovery determination are shown in Table 3-1, indicating that the recovery determination yielded satisfactory results.

[0147] Table 3-1 Results of recovery and precision tests for blank matrix spikes

[0148]

[0149]

[0150] Example 4

[0151] 1. Instruments and reagents

[0152] Same as Example 1 above.

[0153] 2. Chromatographic conditions

[0154] Same as Example 1 above.

[0155] 3. Determination of linearity in the HPLC system

[0156] Same as Example 1 above.

[0157] 4. Sample preparation: Aqueous, oily, creamy, emulsion, gel or powder: Weigh 1g of the sample to be tested into a stoppered colorimetric tube, accurately add 20ml of 90% methanol solution, vortex to mix, sonicate for 15min, centrifuge at 10000rpm for 5min, and filter through a 0.45μm filter membrane to obtain the sample solution to be tested.

[0158] The four compounds, including diaminopyrimidine oxide, in the sample were calculated according to formula (1):

[0159] (1)

[0160] In the formula: ω—content of four compounds, including diaminopyrimidine oxide, in cosmetics, in %;

[0161] m—sample volume, g;

[0162] ρ — the mass concentration of four compounds, including diaminopyrimidine oxide, in the cosmetic sample, calculated by substituting into the standard curve, in μg / mL;

[0163] V – Fixed volume, mL.

[0164] Under chromatographic conditions, the standard working curve solution and the sample solution were injected separately, and qualitative analysis was performed based on the retention time and the spectrum of the diode array. The content of four compounds, including diaminopyrimidine oxide, in the sample solution was determined from the standard curve. The response values ​​of the four compounds, including diaminopyrimidine oxide, in the sample solution should be within the linear range of the standard curve. If they exceed the linear range, the extract should be diluted and measured again, or the amount of extract should be increased and the test repeated.

[0165] The sample determination results are shown in Table 4-1. The extraction method and rapid determination method described in this invention can accurately quantify the content of four compounds, including diaminopyrimidine oxide, in the sample.

[0166] Table 4-1 Results of determination of four compounds, including diaminopyrimidine oxide, in the sample.

[0167] Cosmetic Name Ingredients listed on the label Measured content (%) Cosmetics 1 Diaminopyrimidine oxide 1.025 Cosmetics 2 pyrrolidinyl diaminopyrimidine oxide 0.895

[0168] In summary, the detection method for four compounds, including diaminopyrimidine oxide, in cosmetics according to this invention is simple, rapid, and highly sensitive, with recovery and repeatability meeting the requirements of routine testing. This method possesses high sensitivity, high quality accuracy, and a feasible linear range, greatly improving the monitoring capabilities of testing institutions for cosmetics.

[0169] Those skilled in the art will understand that the above embodiments are specific implementations of this application, and in practical applications, various changes can be made in form and detail without departing from the spirit and scope of this application.

Claims

1. A method for simultaneously detecting diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester in cosmetics, characterized in that, The method includes the steps of: using liquid chromatography to detect whether the cosmetic product contains diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester; wherein the chromatographic conditions of the liquid chromatography include: using an aqueous solution of phosphoric acid as the aqueous phase and methanol as the organic phase for gradient elution, and the gradient elution procedure is as follows: ; The aqueous solution of phosphoric acid has a mass concentration of 85%. The chromatographic conditions also include: Chromatographic column: C18 column; Column temperature: 25-35℃; Flow rate: 0.6-1.2 mL / min; and Injection volume: 5-15 µL; The sample to be tested is selected from at least one of aqueous solutions, oils, creams, emulsions, gels, and powders. The sample to be tested includes a pretreatment step: ultrasonic treatment of the sample to be tested with 90% methanol, then adding n-hexane and mixing, allowing it to stand and separate into layers, and taking the lower clear liquid as the sample solution to be tested; the sample solution to be tested is filtered through a filter membrane. Alternatively, if the sample to be tested is a wax-based sample, the sample to be tested includes a pretreatment step: treating the sample to be tested with tetrahydrofuran, then adding 90% methanol solution and sonicating the sample to be tested, then adding n-hexane and mixing, allowing it to stand and separate into layers, and taking the lower clear liquid as the sample solution to be tested; the sample solution to be tested is filtered through a filter membrane.

2. The method according to claim 1, characterized in that, The liquid chromatography is high-performance liquid chromatography, and the detection wavelengths set on the high-performance liquid chromatography include: Diaminopyrimidine oxide: 287nm; Pyrrolidinyl diaminopyrimidine oxide: 228 nm; Metformin: 233 nm; and Chloroprostanol isopropyl ester: 228 nm.

3. The method according to claim 1, characterized in that, The method includes the following steps: Step 1: Prepare standard solutions of diaminopyrimidine oxide, pyrrolidinyl diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester at different concentrations using methanol as the solvent; Step 2: High performance liquid chromatography (HPLC) was used to detect the different concentrations of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester standard solutions obtained in Step 1. Based on the concentrations of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester and the instrument response values, standard curves for diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester were plotted. Step 3: Detect the sample solution under the same test conditions as in Step 2, and calculate the contents of diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and chloroprostol isopropyl ester based on the standard curve obtained in Step 2.

4. The method according to claim 3, characterized in that, The concentrations of the different concentrations of the diaminopyrimidine oxide, pyrrolidine diaminopyrimidine oxide, metformin, and cloprostenol isopropyl ester standard solutions are selected from at least three of the following: 0.1 μg / mL, 0.5 μg / mL, 1 μg / mL, 5 μg / mL, 10 μg / mL, 50 μg / mL, 100 μg / mL, and 200 μg / mL.

5. The method according to claim 1, characterized in that, The cosmetics mentioned include shampoos, shower gels, conditioners, perm creams, hair masks, hair oils, hair waxes, styling sprays, hair gels, hair creams, hair sunscreen sprays, hair growth serums, beard creams, beard oils, beard growth serums, beard lotions, eyebrow dyes, hair dyes, eyebrow pencils, eyebrow powders, eyebrow growth serums, eyelash growth serums, and eyelash setting serums.

Citation Information

Patent Citations

  • GC-MS combined detection method of N-nitrosodimethylamine in metformin hydrochloride sustained release tablet

    CN112083088A

  • Method for detecting pyrrolizidine alkaloid in cosmetics

    CN117761192A